| 发明名称 |
ANTIBODY SPECIFICALLY BINDING TO GLP-1R AND FUSION PROTEIN THEREOF WITH GLP-1 |
| 摘要 |
Disclosed in the present invention is an antibody specifically binding to GLP-1R and a fusion protein thereof with GLP-1. The fusion proteins can effectively bind to a human GLP-1R receptor and activate a receptor signaling pathway, thus are useful for treating diabetes, excessive weight, obesity and related disorders thereof. |
| 申请公布号 |
US2016362498(A1) |
申请公布日期 |
2016.12.15 |
| 申请号 |
US201414911715 |
申请日期 |
2014.08.01 |
| 申请人 |
GMAX BIOPHARM LLC. |
发明人 |
ZHANG Cheng;JING Shuqian;ZHANG Hua;WANG Xiaofeng;YAO Chenjiang |
| 分类号 |
C07K16/28;C07K14/605 |
主分类号 |
C07K16/28 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. An antibody specifically binding to GLP-1R, comprising an amino acid sequence selected from:
(a) a light chain CDR3 sequence selected from:
light chain CDR3 sequences differing by no more than three amino acid additions, substitutions and/or deletions in total from one of L1-L13 light chain CDR3 sequences: SEQ ID NO: 46 to SEQ ID NO: 53; (b) a heavy chain CDR3 sequence selected from:
heavy chain CDR3 sequences differing by no more than four amino acid additions, substitutions and/or deletions in total from one of H1-H13 heavy chain CDR3 sequences: SEQ ID NO: 20 to SEQ ID NO: 27; and (c) a light chain CDR3 sequence from (a) and a heavy chain CDR3 sequence from (b). |
| 地址 |
Hangzhou CN |
